SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation MISSISSAUGA, ON, Sept. 13, 2018 /CNW/ - Hoffmann-La Roche ...

Herceptin SC contains the active ingredient trastuzumab. Herceptin SC is used to treat breast cancer whose tumour has tested positive to HER2. For more information, see Section 1. Why am I using ...

Results. Twenty-two patients were enrolled. The mean total patient time in the treatment chair was 61.8 minutes shorter with SC versus IV HP (22.5 vs 84.3 minutes, P<0.0001).The mean total patient ...

Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients ... Meredith Venerus, M.Sc., for assistance with the patient-reported ...

Topline data were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki followed by THP in patients with high-risk, locally advanced HER2-positive early stage breast cancer.

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The ...

Patients with early breast cancer when trastuzumab was given as neoadjuvant therapy (RR, 1.30; 95% CI, 0.47-3.59; with consistency across studies, I 2 = 0%; P =.57).

When multiple trastuzumab biosimilars entered the US market in quick succession, they were able to do something other biosimilars have not in the United States: drive down the cost of the ...